|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00419289 |
|
Date of registration:
|
04/01/2007 |
|
Primary sponsor: |
|
|
Public title:
|
Optimizing the Effect of COPD Rehabilitation
|
|
Scientific title:
|
Rehabilitation of COPD Patients: Can the Effect be Prolonged by Follow-up and Continued Rehabilitation |
|
Date of first enrolment:
|
January 2007 |
|
Target sample size:
|
120 |
|
Recruitment status: |
Not yet recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT00419289 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
|
|
|
Countries of recruitment
|
|
Denmark
| | | | | | | |
|
Contacts
|
|
Name:
|
Susanne Vest, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
susanne.vest@dadlnet.dk |
|
Affiliation:
|
|
|
|
Name:
|
Susanne Vest, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
susanne.vest@dadlnet.dk |
|
Affiliation:
|
|
|
|
Name:
|
Susanne Vest, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Glostrup University Hospital, Copenhagen |
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- FEV1 < 60% of expected
Exclusion Criteria:
- Other severe chronic conditions
Age minimum:
N/A
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Chronic Obstructive Pulmonary Disease
|
|
Intervention(s)
|
|
Behavioral: follow-up rehabilitation of participants with COPD
|
|
Primary Outcome(s)
|
|
Disease specific Quality of Life
|
|
Work Capacity
|
|
Secondary Outcome(s)
|
|
Number of days admitted to hospital
|
|
Secondary ID(s)
|
|
KA20060179
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|